Prescription Drug Supply Chain Pricing Transparency Act

S 2198, the Prescription Drug Supply Chain Pricing Transparency Act, directs the Government Accountability Office (GAO) to study how intermediaries in the prescription drug supply chain (like pharmacy benefit managers, insurers, wholesalers, and pharmacies) are paid for services related to drug prices. The GAO must examine fee structures based on drug prices (such as percentage-based fees), potential conflicts of interest, and trends in these practices across different market segments. The study will cover entities including PBMs, drug manufacturers, and rebate negotiators, and must be completed within two years of the bill's enactment. The GAO will then report its findings and recommendations to Congress, but the bill itself does not change current pricing rules or impose new requirements on the industry.